Progressive Supranuclear Palsy — Research Summary
Printed from RareWays (rareways.com.au) on 5 April 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Automated differentiation of parkinsonian disorders: an ROI-based analysis of subcortical shape and cortical surface features.
Dehghan Yousef et al. — Cognitive neurodynamics (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/41647139/
- 2.
REM sleep behavior disorder as a shared motor phenotype: A multidimensional clinical study.
Lanza Giuseppe et al. — Sleep medicine (1 June 2026)
https://pubmed.ncbi.nlm.nih.gov/41780439/
- 3.
Polygonatum Sibiricum polysaccharide ameliorates Alzheimer's disease by alleviating cuproptosis and activating the PI3K/AKT signaling pathway.
Wang Shuping et al. — Journal of ethnopharmacology (10 May 2026)
https://pubmed.ncbi.nlm.nih.gov/41687942/
- 4.
Impact of preference signaling and geographic preferencing on research productivity and regional matching in orthopaedic surgery residency.
Ali Iyad S et al. — American journal of surgery (1 May 2026)
https://pubmed.ncbi.nlm.nih.gov/41713185/
- 5.
Reply to the Letter to the Editor regarding "Clinical implications of progressive ventilatory impairment in multiple system atrophy and progressive supranuclear palsy".
Okubo So et al. — Journal of the neurological sciences (15 April 2026)
https://pubmed.ncbi.nlm.nih.gov/41759418/
Clinical Trials — Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
Recruiting — Phase 3 — Eli Lilly and Company
https://clinicaltrials.gov/study/NCT07321886
- 2.
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Recruiting — Phase 3 — Genmab
https://clinicaltrials.gov/study/NCT06508658
- 3.
WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Recruiting — Phase 2 — Mediar Therapeutics
https://clinicaltrials.gov/study/NCT06967805
- 4.
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Recruiting — Phase 3 — Eli Lilly and Company
https://clinicaltrials.gov/study/NCT07174336
- 5.
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Recruiting — Phase 3 — Akero Therapeutics, Inc
https://clinicaltrials.gov/study/NCT06215716
- 6.
Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products
Recruiting — Medtronic
https://clinicaltrials.gov/study/NCT00271180
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Progressive Supranuclear Palsy
Progressive Supranuclear Palsy is a rare brain disease that causes degeneration of cells in the brainstem and cerebral cortex. It is frequently misdiagnosed as Parkinson's disease. Key features include falls, eye movement abnormalities, stiffness, and cognitive changes. There is no disease-modifying treatment and median survival after diagnosis is 6-7 years.
Most Recent Research
UNLABELLED: The clinical manifestations of early-stage parkinsonian syndromes overlap, making accurate differential diagnosis crucial yet challenging. This study aimed to develop a system for automated differentiation of idiopathic Parkinson's disease (IPD) from progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS). Our sample included clinical data and T1-weighted magnetic resonance imaging from 50 IPD, 47 PSP, and 38 CBS patients. We introduced an atlas-based approach to extract shape features from subcortical regions in each subject's native coordinate image space. The surface thickness and folding parameters were also extracted from cortical regions. A statistical analysis was conducted to identify regions with significant differences in the extracted features, followed by the employment of a feed-forward neural network to distinguish these patients. Significant structural differences were observed in several regions, including the thalamic nuclei, basal ganglia, midbrain, cerebellum, cingulate cortex, and insula. Using only cortical surface features, our diagnostic model outperformed the model that relied solely on subcortical shape features. However, the classifier achieved its best predictive performance when incorporating features from both cortical and subcortical structures, yielding an accuracy of 86.1% in a multi-class classification system and 96.1% for distinguishing IPD from PSP and CBS, as well as an accuracy of 94.2% for classifying CBS versus PSP in a two-class classification system. Our findings underscore the significance of cortical morphological patterns and demonstrate that the proposed methodology could potentially serve as an automated diagnostic system in clinical settings. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11571-025-10402-2.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.